Category Archives: Myocardial Infarction

The incidence of thrombotic complications in patients with coronavirus disease 2019 (COVID-19) admitted to intensive care units (ICUs) appears to be remarkably high, according to the authors of a recent study published in Thrombosis Research. Frederikus A. Klok, MD, PhD, of the department of thrombosis and hemostasis at the Leiden University Medical Center in the Netherlands, and colleagues evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep vein thrombosis, ischemic stroke, myocardial infarction, or systemic arterial embolism in all COVID-19 patients admitted to the ICU of 2 university hospitals and 1 teaching hospital in the Netherlands Continue reading →

INDIANAPOLIS, May 8, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA)approved Retevmo (selpercatinib, 40 mg & 80 mg capsules), the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC),and the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Continue reading →

Patients with chronic lower extremity artery disease (LEAD) treated with a more vs less intensive antithrombotic therapeutic regimen were found to be at lower risk for limb amputation, stroke, and revascularization, according to a study published in the European Heart Journal-Cardiovascular Pharmacotherapy. An estimated 202 million people worldwide are thought to have LEAD Continue reading →

The report on the Global Myocardial Infarction Therapeutics Market features detailed insights and deep research. The report introduces the important factors which driving the growth of the global Myocardial Infarction Therapeutics market, untapped opportunities for the manufacturers, current trends, and developments shaping the global Myocardial Infarction Therapeutics market and other factors across various key segments. In addition, report highlights the market drivers, future opportunities and restraints which impacting the growth of the global Myocardial Infarction Therapeutics market Continue reading →

The frequency, characteristics and outcomes of acutemyocardial infarction(AMI) during exacerbation of chronic obstructive pulmonary disease (COPD) are unknown. Adult patients hospitalized with a principle diagnosis of acute COPD exacerbation were identified using retrospective analysis of the Nationwide Inpatient Sample (NIS) from 2003 to 2016. Patients were stratified into 2-groups with and without a secondary diagnosis of AMI Continue reading →

Abstract Objective To evaluate the prognosis of unrecognised myocardial infarction determined by electrocardiography (UMI-ECG) or cardiac magnetic resonance imaging (UMI-CMR). Design Systematic review and meta-analysis of prospective studies. Continue reading →

AIMS: The evidence are not conclusive that a small incremental increase in door-to-balloon (D2B) time leads to a significant increase in death of ST-elevationmyocardial(STEMI) patients. In a previous study we described a quality improvement intervention that reduced D2B time in 333 patients with STEMI. The aim of the current study was to compare mortality rates of the patients, before and after the intervention. Continue reading →

The Global Myocardial Infarction Drug Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Continue reading →

Zoll Medical Corp., of Chelmsford, Mass., received CE mark approval to market its second-generation Supersaturated Oxygen (SSO2) Therapy in Europe and other countries that accept CE mark. The therapy, which delivers hyperbaric levels of oxygen to the ischemic heart muscle immediately following percutaneous coronary intervention, has been shown to significantly reduce damage to the heart muscle after an acute myocardial infarction. "SSO2 Therapy will support clinicians in delivering the highest quality of care for their [ST-elevation myocardial infarction] patients in Europe and other countries that accept CE mark," said Neil Johnston, president, Zoll Circulation. Continue reading →

The Fourth Universal Definition ofMyocardial Infarction(FUDMI) [published simultaneously in 2018 in numerous journals including Circulation, Journal of the American College of Cardiology and European Heart Journal] focuses mainly on the distinction between non-ischemicmyocardialinjury andmyocardial infarction(MI), along with the role of cardiovascular magnetic resonance, in order to define the etiology ofmyocardialinjury. Continue reading →